850074-18-9

Basic information

• Product Name: ethyl 5-formylbenzothiophene-2-carboxylate
• Synonyms: ethyl 5-formyl-1-benzothiophene-2-carboxylate; Ethyl-5-formyl-1-benzothiophen-2-carboxylat
• CAS NO: 850074-18-9
• Molecular Formula: C₁₂H₁₀O₃S
• Molecular Weight: 234.27
• Mol File: 850074-18-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 384.8°C at 760 mmHg
• Flash Point: 186.5°C
• Density: 1.308g/cm³
• Vapor Pressure: 3.97E-06mmHg at 25°C
• Refractive Index: 1.653
• CAS DataBase Reference: ethyl 5-formylbenzothiophene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-formylbenzothiophene-2-carboxylate(850074-18-9)
• EPA Substance Registry System: ethyl 5-formylbenzothiophene-2-carboxylate(850074-18-9)

Safety Data

• Hazardous Substances Data: 850074-18-9(Hazardous Substances Data)

Upstream product

• 67242-59-5 N-methyl-N-(2-pyridyl)-formamide 
• 25785-09-5 ethyl 5-nitro-2-benzo[b]thiophenecarboxylate 
• 25785-10-8 ethyl 5-amino-1-benzothiophene-2-carboxylate 
• 13771-70-5 5-iodo-benzo[b]thiophene-2-carboxylic acid ethyl ester 

Downstream Products

• 530145-02-9 ethyl 5-(hydroxymethyl)-1-benzothiophene-2-carboxylate 
• 947513-36-2 C₁₈H₁₇NSO₂ 
• 947513-37-3 C₁₉H₁₉NSO₂ 
• 850074-19-0 5-[(3-methoxy-benzylamino)-methyl]-benzo[b]thiophene-2-carboxylic acid hydroxyamide 
• 947513-39-5 C₂₀H₂₁NSO₂ 

Relevant articles and documents

Benzo[b]thiophene-based histone deacetylase inhibitors

Benzo[b]thienyl hydroxamic acids, a novel class of histone deacetylase (HDAC) inhibitors, were identified via a targeted screen of small molecule hydroxamic acids. Various substitutions were explored in the C5- and C6-positions of the benzo[b]thiophene co

BENZOTHIOPHENE DERIVATIVES

The present invention relates to a novel class of benzothiophene amide derivatives. The hydroxamic acid compounds can be used to treat cancer. The benzothiophene amide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.